JPRN-UMIN000009674招募中未知
Prediction of acute GVHD following hematopoietic stem cell transplantation by using MLR-ELISPOT assay - Prediction of acute GVHD by MLR- ELISPOT assay
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patient that quantity of blood sampling is regarded as a physical burden for reasons of the age or the body weight.
研究者
相似试验
进行中（未招募）
不适用
Treatment of severe acute GVHD after allogeneic hematopoietic stem cell transplantation with steroids versus MSC and steroids.A prospective double-blind placebo-controlled randomized phase III trialGraft Versus Host DiseaseMedDRA version: 18.0Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 18.0Level: LLTClassification code 10068908Term: AGVHDSystem Organ Class: 10021428 - Immune system disordersEUCTR2011-003237-33-NLHOVON Foundation200
进行中（未招募）
1 期
Preventie van ernstige Graft versus Host ziekte na allogene stamcel transplantatie gegeven als immuuntherapie voor patienten met een hematologische ziekte. Een gerandomiseerde fase III studie (HOVON 96 GVHD).Graft versus Host DiseaseMedDRA version: 20.0Level: LLTClassification code 10018799Term: GVHDSystem Organ Class: 100000004870EUCTR2008-003540-11-NLHOVON Foundation500
已完成
3 期
Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase III trial.Graft versus Host Disease10018849NL-OMON47822HOVO497
进行中（未招募）
不适用
Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase III trial. - HOVON 96 GVHDGraft versus Host DiseaseEUCTR2008-003540-11-BEHOVON Foundation500
招募中
不适用
Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase III trial.Randomization 1: Patients planned to undergo an allogeneic SCT formalignant hematological disorders and with a related or unrelated 8/8 HLA matched donor.NL-OMON28315Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl500